Allometric Pharmacokinetic Scaling
Also known as: allometric scaling, inter-species extrapolation, FIH dose prediction
Allometric scaling is a mathematical approach for predicting human pharmacokinetics from preclinical animal data using body weight relationships. Developed systematically by Mordenti and colleagues in the late 1980s, it enables rational first-in-human dose prediction without assuming species-specific metabolic differences.
Key highlights
- Simple mathematical approach requiring only animal PK data and body weights
- No mechanistic assumptions about metabolism or clearance; model-free scaling
- Regulatory acceptance; FDA and EMA guidance explicitly recommend allometric scaling for FIH dose estimation
- Flexible; applicable to clearance, volume of distribution, and other PK parameters
Intuition
This section is available to Pro members. Upgrade to Pro
How it works
This section is available to Pro members. Upgrade to Pro
When to use it
Use allometric scaling to predict human first-in-human doses during early drug development, when human data are unavailable. It is required by regulatory agencies (FDA, EMA) for IND justification and dose escalation planning.
Strengths & limitations
- Simple mathematical approach requiring only animal PK data and body weights
- No mechanistic assumptions about metabolism or clearance; model-free scaling
- Regulatory acceptance; FDA and EMA guidance explicitly recommend allometric scaling for FIH dose estimation
- Flexible; applicable to clearance, volume of distribution, and other PK parameters
- Allometric exponents vary by parameter and drug; assuming a fixed exponent (e.g., 0.75) may not apply to all drugs
- Requires PK data from multiple species; not feasible for compounds studied in only one animal species
- Assumes similar drug metabolism pathways across species; may fail for species-specific metabolic patterns
- Does not account for species differences in absorption, distribution, or protein binding
Common pitfalls
This section is available to Pro members. Upgrade to Pro
Applications
This section is available to Pro members. Upgrade to Pro
Frequently asked
What is the typical allometric exponent for drug clearance?
For most drugs, drug clearance scales with body weight to the 0.67-0.75 exponent. This range reflects the balance between organ size (which scales with weight^0.67) and metabolic rate (which scales with weight^0.75). Default exponent is often taken as 0.75 (Kleiber's law for metabolic rate).
How many animal species do I need for allometric scaling?
Ideally, data from 3-4 species (e.g., mouse, rat, dog, primate) provides a robust power-law fit. Two species may be sufficient if the fit is strong, but regulatory agencies prefer more data points for confidence.
Does allometric scaling work for all drugs?
Allometric scaling works well for drugs metabolized by common pathways (e.g., hepatic oxidation). It is less reliable for drugs with species-specific transporters or unusual metabolism. Always validate assumptions about drug metabolism before applying scaling.
How do I translate allometrically scaled clearance to a first-in-human dose?
Use the predicted human clearance to estimate a safe dose based on toxicology findings and desired exposure level. Apply safety margins (typically 10-fold for systemic toxicity, 2-5-fold for pharmacology) to the maximum non-toxic dose from animals, then adjust for human clearance.
Sources
- 1.Mordenti, J., & Chappell, W. (1989). The use of allometric scaling in toxicokinetic studies. Fundamental and Applied Toxicology, 13(2), 335-346.
- 2.Feng, M. R., Chiang, S. T., & Grammatoglou, G. (2011). Allometric scaling of blood clearance from preclinical species to humans. Journal of Pharmaceutical and Biomedical Analysis, 21(2), 195-205.
You have read it. What now?
Cite this page
ScholarGate. (2026, June 3). Allometric PK Scaling. ScholarGate. https://scholargate.app/pharmacology/allometric-pk-scaling